{
  "query": "NVO",
  "resolved": {
    "ticker": "NVO",
    "cik": "0000353278",
    "title": "NOVO NORDISK A S"
  },
  "signals": [
    {
      "type": "trial_to_filing",
      "headline": "NOVO NORDISK A S (NVO) — PHASE1 primary completion in ~143 days",
      "entity": "Novo Nordisk A/S",
      "ticker": "NVO",
      "cik": "0000353278",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE1)",
        "detail": "A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity",
        "nctId": "NCT07566390",
        "date": "2026-12-26"
      },
      "observed": {
        "event": "primary completion in ~143 days",
        "nctId": "NCT07566390"
      },
      "predicted": {
        "event": "SEC 8-K / press release on Phase 2 readout / advance",
        "leadTime": "12-24 mo",
        "baseRate": 0.52,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 52% (Wong/Siah/Lo 2019)",
      "confidence": 0.55,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07566390",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "NOVO NORDISK A S (NVO) — PHASE3 protocol updated 1 days ago",
      "entity": "Novo Nordisk A/S",
      "ticker": "NVO",
      "cik": "0000353278",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE3)",
        "detail": "AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight",
        "nctId": "NCT07533175",
        "date": "2028-08-07"
      },
      "observed": {
        "event": "protocol updated 1 days ago",
        "nctId": "NCT07533175"
      },
      "predicted": {
        "event": "SEC 8-K / press release on NDA/BLA filing (FDA submission)",
        "leadTime": "12-24 mo",
        "baseRate": 0.58,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 57% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07533175",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "NOVO NORDISK A S (NVO) — PHASE3 protocol updated 1 days ago",
      "entity": "Novo Nordisk A/S",
      "ticker": "NVO",
      "cik": "0000353278",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE3)",
        "detail": "AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea",
        "nctId": "NCT07571109",
        "date": "2028-06-26"
      },
      "observed": {
        "event": "protocol updated 1 days ago",
        "nctId": "NCT07571109"
      },
      "predicted": {
        "event": "SEC 8-K / press release on NDA/BLA filing (FDA submission)",
        "leadTime": "12-24 mo",
        "baseRate": 0.58,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 57% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07571109",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "NOVO NORDISK A S (NVO) — PHASE3 protocol updated 2 days ago",
      "entity": "Novo Nordisk A/S",
      "ticker": "NVO",
      "cik": "0000353278",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE3)",
        "detail": "Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide",
        "nctId": "NCT07220759",
        "date": "2027-05-12"
      },
      "observed": {
        "event": "protocol updated 2 days ago",
        "nctId": "NCT07220759"
      },
      "predicted": {
        "event": "SEC 8-K / press release on NDA/BLA filing (FDA submission)",
        "leadTime": "12-24 mo",
        "baseRate": 0.58,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 57% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07220759",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "NOVO NORDISK A S (NVO) — PHASE3 protocol updated 1 days ago",
      "entity": "Novo Nordisk A/S",
      "ticker": "NVO",
      "cik": "0000353278",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE3)",
        "detail": "A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes",
        "nctId": "NCT03811561",
        "date": "2027-11-07"
      },
      "observed": {
        "event": "protocol updated 1 days ago",
        "nctId": "NCT03811561"
      },
      "predicted": {
        "event": "SEC 8-K / press release on NDA/BLA filing (FDA submission)",
        "leadTime": "12-24 mo",
        "baseRate": 0.58,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 57% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT03811561",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278&type=8-K"
      }
    }
  ],
  "recentFilings": {
    "name": "NOVO NORDISK A S",
    "sicDescription": "Pharmaceutical Preparations",
    "filings": []
  },
  "disclaimer": "Research/informational. NOT investment advice.",
  "generatedAt": "2026-08-05T09:00:27.014Z"
}